PRTA earnings: next report 2026-08-03, real EPS beat/miss history, analyst consensus Buy, P/E -3.00. Updated 2026-07-23.
Prothena (PRTA) Research Hub
Prothena (PRTA) trades on NASDAQ, IE in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 8.93 USD (-3.98%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.00, market cap 0.45B. This hub links to the full technical, earnings and options research available for PRTA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IE |
| Last close | 8.93 USD (-3.98%) |
| 52-week range | 7.93 USD – 10.15 USD |
| Trend regime | Range |
| 14-day RSI | 52.8 (Neutral) |
| Trailing P/E | -3.00 |
| Market cap | 0.45B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-03 |
Available research for PRTA
Covered Call on PRTA: how it works, illustrative setup around the real 8.93 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PRTA: how it works, illustrative setup around the real 8.93 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PRTA: how it works, illustrative setup around the real 8.93 USD price, max profit/loss, breakeven and when to use it. Educational.
PRTA technical analysis: range, last 8.93 USD, RSI 52.8, 52w range 7.93 USD–10.15 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PRTA in?
Prothena (PRTA) is classified under Healthcare (Biotechnology), listed on NASDAQ, IE.
Is PRTA in an uptrend or downtrend?
As of 2026-09-11, PRTA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PRTA's trailing P/E ratio?
PRTA's trailing P/E is -3.00, with a market cap of 0.45B. See the earnings research page for full valuation detail.
When does PRTA next report earnings?
PRTA is next scheduled to report earnings on 2026-08-03, with a consensus EPS estimate of -0.39 USD.